Pontiano Kaleebu

Last updated

Pontiano Kaleebu
Born1960 (age 62–63)
Uganda
NationalityUgandan
CitizenshipUganda
Alma mater Makerere University
(Bachelor of Medicine and Bachelor of Surgery)
University of London
(Diploma in Immunology)
(Doctor of Philosophy in Immunology)
Occupation(s)Physician, Academic
Clinical Immunologist
HIV/AIDS Researcher
and Medical Administrator
Years active1995 – present
Known forProfessional competence
Title Executive Director of Uganda Virus Research Institute

Pontiano Kaleebu is a Ugandan physician, clinical immunologist, HIV/AIDS researcher, academic and medical administrator, who is the executive director of the Uganda Virus Research Institute. [1]

Contents

He also concurrently serves as the director of the joint clinical research unit owned by the Medical Research Council (United Kingdom), the Uganda Virus Research Institute, and the London School of Hygiene & Tropical Medicine, located in Entebbe, Uganda, carrying on research in infectious, non-communicable and neglected diseases. [1] [2]

Background and education

Pontiano Kaleebu was born in Uganda, circa 1960. [3] He attended Jinja Kaloli Primary School, in Wakiso District, where he obtained his Primary Leaving Certificate. He then transferred to St. Mary's College Kisubi, where he undertook his O-Level studies. He completed his A-Level education at Kampala High School, where he obtained his High School Diploma. [3]

He was admitted to Makerere University School of Medicine, where he graduated with a Bachelor of Medicine and Bachelor of Surgery degree in the mid 1980s. He interned at St. Francis Hospital Nsambya, under Dr. Merriam Duggan. [3]

In 1988, Kaleebu was awarded a scholarship to study immunology at the Royal Postgraduate Medical School, at Hammersmith Hospital, in West London, in the United Kingdom. He graduated with a Diploma in Immunology. [3]

While in London, he was offered the opportunity to pursue a doctorate in immunology, by the University of London, on scholarship, under Professor Jonathan Weber, at St Mary's Hospital, London. He completed his PhD program in the mid 1990s. [1] [3]

Career

1987, Kaleebu was recruited as a medical research officer at the Uganda Virus Research Institute, by its director, Dr. Sylvester Sempala. Following the completion of his PhD studies, Kaleebu returned to the institute and was appointed as the head of the immunology department. The following year, he joined the joint research programme at the Medical Research Council and the Uganda Virus Research Institute. [3]

Over the years, Dr Kaleebu has become a leading international researcher in the areas of immunology and virology and is a member to the international team that participated the first vaccine trial in Africa against HIV/AIDS. In the late 2000s, he became the director of the Uganda Virus Research Institute in an acting capacity. [3] He was confirmed in that position in the mid-2010s. He is a Professor of immunovirology at the London School of Hygiene and Tropical Medicine. [4]

Other considerations

His main research interests are HIV vaccine research especially understanding HIV diversity and resistance to antiretroviral drugs, as well as the protective immune responses. He is the recipient of numerous Awards including (a) the Scientific Achievement Award from Rotary International, awarded in 2003 (b) the Presidential Science Award 2005/2006 and (c) the Fellowship of Imperial College London, Faculty of Medicine, awarded in 2010 (d) Fellow of the Royal College of Physicians of Edinburgh- FRCP Edin 2016 (e) Fellow of the Academy of Medical Sciences-FMedSci 2020. (f) Fellow of the Uganda National Academy of Science-FUNAS 2021. He has co-authored more than 260 publications in peer reviewed journals. [1] Some of his most cited publications include; Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis (2019), [5] HIV subtype diversity worldwide (2019), [6] Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania (2019), [7] HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis (2018), [8] Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease (2016), [9] Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (2016), [10] The African genome variation project shapes medical genetics in Africa (2015), [11] Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015), [12] A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia (2015), [13] Towards host-directed therapies for tuberculosis (2015), [14] Randomised controlled trials for Ebola: practical and ethical issues (2014), [15] Immune activation alters cellular and humoral responses to yellow fever 17D vaccine (2014), [16] Pregnancy, parturition and preeclampsia in women of African ancestry (2014), [17] Discovery and refinement of loci associated with lipid levels (2013), [18] Common variants associated with plasma triglycerides and risk for coronary artery disease (2013), [19] Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis (2013), [20] High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda (2012), [21] HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda (2011), [22] Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa (2011), [23] CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa (2009), [24] Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa (2008), [25] Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort (2007), [26] The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis (2004), [27] Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1—positive persons in Uganda (2002), [28] Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort (2001), [29] Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterization (1996) [30]

Awards

He received a medal of service from the government of the Republic of Uganda [31]

Related Research Articles

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine against smallpox and mpox, having fewer side effects than smallpox vaccines derived from other poxviruses.

Following infection with HIV-1, the rate of clinical disease progression varies between individuals. Factors such as host susceptibility, genetics and immune function, health care and co-infections as well as viral genetic variability may affect the rate of progression to the point of needing to take medication in order not to develop AIDS.

Immunogenicity is the ability of a foreign substance, such as an antigen, to provoke an immune response in the body of a human or other animal. It may be wanted or unwanted:

HIV superinfection is a condition in which a person with an established human immunodeficiency virus infection acquires a second strain of HIV, often of a different subtype. These can form a recombinant strain that co-exists with the strain from the initial infection, as well from reinfection with a new virus strain, and may cause more rapid disease progression or carry multiple resistances to certain HIV medications.

<span class="mw-page-title-main">Vaccine efficacy</span> Reduction of disease among the vaccinated comparing to the unvaccinated

Vaccine efficacy or vaccine effectiveness is the percentage reduction of disease cases in a vaccinated group of people compared to an unvaccinated group. For example, a vaccine efficacy or effectiveness of 80% indicates an 80% decrease in the number of disease cases among a group of vaccinated people compared to a group in which nobody was vaccinated. When a study is carried out using the most favorable, ideal or perfectly controlled conditions, such as those in a clinical trial, the term vaccine efficacy is used. On the other hand, when a study is carried out to show how well a vaccine works when they are used in a bigger, typical population under less-than-perfectly controlled conditions, the term vaccine effectiveness is used.

<span class="mw-page-title-main">Subtypes of HIV</span> Variants of the human immunodeficiency virus

The subtypes of HIV include two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa, while HIV-2 viruses are related to viruses found in the sooty mangabey, a vulnerable West African primate. HIV-1 viruses can be further divided into groups M, N, O and P. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Group M can be further subdivided into subtypes based on genetic sequence data. Some of the subtypes are known to be more virulent or are resistant to different medications. Likewise, HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses, although HIV-2 is also known to cause AIDS. One of the obstacles to treatment of the human immunodeficiency virus (HIV) is its high genetic variability.

The United States Military HIV Research Program was initiated by the United States Congress in 1986, in reaction to the threat of lost effectiveness of U.S./Allied troops due to HIV infection. The mission of MHRP is to develop an HIV-1 vaccine, provide prevention, care, and treatment, and conduct meaningful HIV/AIDS research for the global community through the President's Emergency Plan for AIDS Relief (PEPFAR). It is centered at the Walter Reed Army Institute of Research (WRAIR), and has established five international research sites in Africa and Asia. MHRP also partners with the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Thailand. MHRP works closely with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), most notably in the development of the RV144 HIV vaccine in Thailand. MHRP is the largest research program supported by the HJF.

MVA-B, or Modified Vaccinia Ankara B, is an HIV vaccine created to give immune resistance to infection by the human immunodeficiency virus. It was developed by a team of Spanish researchers at the Spanish National Research Council's Biotechnology National Centre headed by Dr. Mariano Esteban. The vaccine is based on the Modified vaccinia Ankara (MVA) virus used during the 1970s to help eradicate the smallpox virus. The B in the name "refers to HIV-B, the most common HIV subtype in Europe". It has been stated by Dr. Esteban that, in the future, the vaccine could potentially reduce the virulence of HIV to a "minor chronic infection akin to herpes".

<span class="mw-page-title-main">Elioda Tumwesigye</span> Ugandan politician

Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. From March 2015 until June 2016, he served as the minister of health.

Anna-Lise WilliamsonMASSAf is a Professor of Virology at the University of Cape Town. Williamson obtained her PhD from the University of the Witwatersrand in 1985. Her area of expertise is human papillomavirus, but is also known on an international level for her work in developing vaccines for HIV. These vaccines have been introduce in phase 1 of clinical trial. Williamson has published more than 120 papers.

Moses R Kamya, is a Ugandan physician, academic, researcher and academic administrator, who serves as Professor and Chair of the Department Medicine, Makerere University School of Medicine, a component of Makerere University College of Health Sciences.

Roy D. Mugerwa was a Ugandan physician, cardiologist and researcher. His contribution to the world of academics include being a Professor Emeritus at Makerere University College of Health Sciences in Kampala, cardiology in Uganda, researching HIV/AIDS and tuberculosis, and his efforts to find an effective HIV vaccine.

Alash'le Grace Abimiku is a Nigerian executive director of the International Research Centre of Excellence at the Institute of Human Virology Nigeria and a professor of virology at the University of Maryland School of Medicine.

Robert Steffen is an Emeritus Professor at the Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland and an adjunct professor at the University of Texas School of Public in Houston. He is an editor of the Journal of Travel Medicine.

<span class="mw-page-title-main">Epidemiology of Hepatitis D</span> Instance, distribution, and control of Hepatitis D

The epidemiology of hepatitis D occurs worldwide. Although the figures are disputed, a recent systematic review suggests that up to 60 million individuals could be infected. The major victims are the carriers of the hepatitis B surface antigen (HBsAg), who become superinfected by the HDV, and intravenous drug users who are the group at highest risk. The infection usually results in liver damage ; this is most often a chronic and severe hepatitis rapidly conducive to cirrhosis.

Fred Mhalu is a microbiologist and medical researcher from Tanzania. His main area of study revolves around infectious diseases and intervention. Ever since 1986, he has been a main contributor to the information about AIDS in Africa. As a co-coordinator of a Tanzanian-Swedish research collaboration called TANSWED, he was involved in many research projects that lead to multiple publications in medical journals. His more recent research on HIV/AIDS involves studying breast cancer in HIV prevalent areas, evaluating prevention of mother-to-child-transmission of HIV-1, and observing sexual behaviors of high risk populations for HIV-1.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

<span class="mw-page-title-main">Frits van Griensven</span> Dutch public health scientist and epidemiologist

Godefridus Johannes Petrus "Frits" van Griensven is a pioneering Dutch scientist in epidemiology, sociology and public health. Most of his work is on addressing the HIV epidemic among men who have sex with men and other HIV key populations.

References

  1. 1 2 3 4 "Profile of Professor Pontiano Kaleebu". Entebbe: Medical Research Council (Uganda). 2018. Retrieved 4 December 2018.
  2. ↑ Ainebyoona, Emmanuel (14 May 2018), "UVRI partners with London school for cancer research", Daily Monitor , Kampala, retrieved 4 December 2018
  3. 1 2 3 4 5 6 7 Kalibbala, Gladys (29 November 2009). "Kaleebu came home to find cure for AIDS". New Vision . Kampala. Retrieved 4 December 2018.
  4. ↑ "Meet Prof. Pontiano Kaleebu: UVRI's new Director". Atlanta: International Association of National Public Health Institutes. 3 August 2016. Retrieved 4 December 2018.
  5. ↑ Hemelaar, Joris; Elangovan, Ramyiadarsini; Yun, Jason; Dickson-Tetteh, Leslie; Fleminger, Isabella; Kirtley, Shona; Williams, Brian; Gouws-Williams, Eleanor; Ghys, Peter D; Abimiku, Alash'le G; Agwale, Simon (1 February 2019). "Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis". The Lancet Infectious Diseases. 19 (2): 143–155. doi:10.1016/S1473-3099(18)30647-9. ISSN   1473-3099. PMID   30509777. S2CID   54485664.
  6. ↑ Bbosa, Nicholas; Kaleebu, Pontiano; Ssemwanga, Deogratius (2019). "HIV subtype diversity worldwide". Current Opinion in HIV and AIDS. 14 (3): 153–160. doi: 10.1097/COH.0000000000000534 . ISSN   1746-630X. PMID   30882484. S2CID   81977044.
  7. ↑ "Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania". The Journal of Infectious Diseases. Retrieved 26 May 2022.
  8. ↑ Gupta, Ravindra K; Gregson, John; Parkin, Neil; Haile-Selassie, Hiwot; Tanuri, Amilcar; Andrade Forero, Liliana; Kaleebu, Pontiano; Watera, Christine; Aghokeng, Avelin; Mutenda, Nicholus; Dzangare, Janet (1 March 2018). "HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis". The Lancet Infectious Diseases. 18 (3): 346–355. doi:10.1016/S1473-3099(17)30702-8. ISSN   1473-3099. PMC   5835664 . PMID   29198909.
  9. ↑ Zanoni, Paolo; Khetarpal, Sumeet A.; Larach, Daniel B.; Hancock-Cerutti, William F.; Millar, John S.; Cuchel, Marina; DerOhannessian, Stephanie; Kontush, Anatol; Surendran, Praveen; Saleheen, Danish; Trompet, Stella (11 March 2016). "Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease". Science. 351 (6278): 1166–1171. Bibcode:2016Sci...351.1166Z. doi:10.1126/science.aad3517. ISSN   0036-8075. PMC   4889017 . PMID   26965621.
  10. ↑ Gregson, John; Tang, Michele; Ndembi, Nicaise; Hamers, Raph L; Rhee, Soo-Yon; Marconi, Vincent C; Diero, Lameck; Brooks, Katherine A; Theys, Kristof; Rinke de Wit, Tobias; Arruda, Monica (1 May 2016). "Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study". The Lancet Infectious Diseases. 16 (5): 565–575. doi:10.1016/S1473-3099(15)00536-8. ISSN   1473-3099. PMC   4835583 . PMID   26831472.
  11. ↑ Gurdasani, Deepti; Carstensen, Tommy; Tekola-Ayele, Fasil; Pagani, Luca; Tachmazidou, Ioanna; Hatzikotoulas, Konstantinos; Karthikeyan, Savita; Iles, Louise; Pollard, Martin O.; Choudhury, Ananyo; Ritchie, Graham R. S. (2015). "The African Genome Variation Project shapes medical genetics in Africa". Nature. 517 (7534): 327–332. Bibcode:2015Natur.517..327G. doi:10.1038/nature13997. ISSN   1476-4687. PMC   4297536 . PMID   25470054. S2CID   4463627.
  12. ↑ Rhee, Soo-Yon; Blanco, Jose Luis; Jordan, Michael R.; Taylor, Jonathan; Lemey, Philippe; Varghese, Vici; Hamers, Raph L.; Bertagnolio, Silvia; Wit, Tobias F. Rinke de; Aghokeng, Avelin F.; Albert, Jan (7 April 2015). "Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis". PLOS Medicine. 12 (4): e1001810. doi: 10.1371/journal.pmed.1001810 . ISSN   1549-1676. PMC   4388826 . PMID   25849352.
  13. ↑ Nakimuli, Annettee; Chazara, Olympe; Hiby, Susan E.; Farrell, Lydia; Tukwasibwe, Stephen; Jayaraman, Jyothi; Traherne, James A.; Trowsdale, John; Colucci, Francesco; Lougee, Emma; Vaughan, Robert W. (20 January 2015). "A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia". Proceedings of the National Academy of Sciences. 112 (3): 845–850. Bibcode:2015PNAS..112..845N. doi: 10.1073/pnas.1413453112 . ISSN   0027-8424. PMC   4311823 . PMID   25561558.
  14. ↑ Zumla, Alimuddin; Chakaya, Jeremiah; Hoelscher, Michael; Ntoumi, Francine; Rustomjee, Roxana; Vilaplana, Cristina; Yeboah-Manu, Dorothy; Rasolofo, Voahangy; Munderi, Paula; Singh, Nalini; Aklillu, Eleni (2015). "Towards host-directed therapies for tuberculosis". Nature Reviews Drug Discovery. 14 (8): 511–512. doi:10.1038/nrd4696. ISSN   1474-1784. PMID   26184493. S2CID   7418745.
  15. ↑ Adebamowo, Clement; Bah-Sow, Oumou; Binka, Fred; Bruzzone, Roberto; Caplan, Arthur; Delfraissy, Jean-François; Heymann, David; Horby, Peter; Kaleebu, Pontiano; Tamfum, Jean-Jacques Muyembe; Olliaro, Piero (18 October 2014). "Randomised controlled trials for Ebola: practical and ethical issues". The Lancet. 384 (9952): 1423–1424. doi:10.1016/S0140-6736(14)61734-7. ISSN   0140-6736. PMC   4392883 . PMID   25390318.
  16. ↑ Muyanja, Enoch; Ssemaganda, Aloysius; Ngauv, Pearline; Cubas, Rafael; Perrin, Helene; Srinivasan, Divya; Canderan, Glenda; Lawson, Benton; Kopycinski, Jakub; Graham, Amanda S.; Rowe, Dawne K. (1 July 2014). "Immune activation alters cellular and humoral responses to yellow fever 17D vaccine". The Journal of Clinical Investigation. 124 (7): 3147–3158. doi:10.1172/JCI75429. ISSN   0021-9738. PMC   4071376 . PMID   24911151.
  17. ↑ Nakimuli, Annettee; Chazara, Olympe; Byamugisha, Josaphat; Elliott, Alison M.; Kaleebu, Pontiano; Mirembe, Florence; Moffett, Ashley (1 June 2014). "Pregnancy, parturition and preeclampsia in women of African ancestry". American Journal of Obstetrics and Gynecology. 210 (6): 510–520.e1. doi:10.1016/j.ajog.2013.10.879. ISSN   0002-9378. PMC   4046649 . PMID   24184340.
  18. ↑ Consortium, Global Lipids Genetics (2013). "Discovery and refinement of loci associated with lipid levels". Nature Genetics. 45 (11): 1274–1283. doi:10.1038/ng.2797. ISSN   1061-4036. PMC   3838666 . PMID   24097068.
  19. ↑ Do, Ron; Willer, Cristen J.; Schmidt, Ellen M.; Sengupta, Sebanti; Gao, Chi; Peloso, Gina M.; Gustafsson, Stefan; Kanoni, Stavroula; Ganna, Andrea; Chen, Jin; Buchkovich, Martin L. (2013). "Common variants associated with plasma triglycerides and risk for coronary artery disease". Nature Genetics. 45 (11): 1345–1352. doi:10.1038/ng.2795. ISSN   1546-1718. PMC   3904346 . PMID   24097064.
  20. ↑ "Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis". International Journal of Epidemiology. Retrieved 26 May 2022.
  21. ↑ Seeley, Janet; Nakiyingi-Miiro, Jessica; Kamali, Anatoli; Mpendo, Juliet; Asiki, Gershim; Abaasa, Andrew; De Bont, Jan; Nielsen, Leslie; Kaleebu, Pontiano (2012). "High HIV Incidence and Socio-Behavioral Risk Patterns in Fishing Communities on the Shores of Lake Victoria, Uganda". Sexually Transmitted Diseases. 39 (6): 433–439. doi: 10.1097/OLQ.0b013e318251555d . ISSN   0148-5717. JSTOR   44981712. PMID   22592828. S2CID   44811502.
  22. ↑ Asiki, Gershim; Mpendo, Juliet; Abaasa, Andrew; Agaba, Collins; Nanvubya, Annet; Nielsen, Leslie; Seeley, Janet; Kaleebu, Pontiano; Grosskurth, Heiner; Kamali, Anatoli (2011). "HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda". Sexually Transmitted Infections. 87 (6): 511–515. doi:10.1136/sti.2010.046805. ISSN   1472-3263. PMID   21835763. S2CID   332068.
  23. ↑ Price, Matt A.; Wallis, Carole L.; Lakhi, Shabir; Karita, Etienne; Kamali, Anatoli; Anzala, Omu; Sanders, Eduard J.; Bekker, Linda-Gail; Twesigye, Rogers; Hunter, Eric; Kaleebu, Pontiano (1 January 2011). "Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa". AIDS Research and Human Retroviruses. 27 (1): 5–12. doi:10.1089/aid.2010.0030. ISSN   0889-2229. PMC   3045073 . PMID   21091377.
  24. ↑ Karita, Etienne; Ketter, Nzeera; Price, Matt A.; Kayitenkore, Kayitesi; Kaleebu, Pontiano; Nanvubya, Annet; Anzala, Omu; Jaoko, Walter; Mutua, Gaudensia; Ruzagira, Eugene; Mulenga, Joseph (6 February 2009). "CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa". PLOS ONE. 4 (2): e4401. Bibcode:2009PLoSO...4.4401K. doi: 10.1371/journal.pone.0004401 . ISSN   1932-6203. PMC   2632744 . PMID   19197365.
  25. ↑ Jaoko, Walter; Nakwagala, Frederick N.; Anzala, Omu; Manyonyi, Gloria Omosa; Birungi, Josephine; Nanvubya, Annet; Bashir, Farah; Bhatt, Kirana; Ogutu, Hilda; Wakasiaka, Sabina; Matu, Lucy (23 May 2008). "Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa". Vaccine. 26 (22): 2788–2795. doi:10.1016/j.vaccine.2008.02.071. ISSN   0264-410X. PMID   18440674.
  26. ↑ Kaleebu, Pontiano; Nankya, Immaculate L.; Yirrell, David L.; Shafer, Leigh Anne; Kyosiimire-Lugemwa, Jacqueline; Lule, Daniel B.; Morgan, Dilys; Beddows, Simon; Weber, Jonathan; Whitworth, James A. G. (1 May 2007). "Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort". Journal of Acquired Immune Deficiency Syndromes. 45 (1): 28–33. doi: 10.1097/QAI.0b013e3180385aa0 . ISSN   1525-4135. PMID   17310935. S2CID   11067305.
  27. ↑ Campbell, Grant R.; Pasquier, Eddy; Watkins, Jennifer; Bourgarel-Rey, Veronique; Peyrot, Vincent; Esquieu, Didier; Barbier, Pascale; Mareuil, Jean de; Braguer, Diane; Kaleebu, Pontiano; Yirrell, David L. (12 November 2004). "The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis *". Journal of Biological Chemistry. 279 (46): 48197–48204. doi: 10.1074/jbc.M406195200 . ISSN   0021-9258. PMID   15331610.
  28. ↑ "Effect of Human Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease Progression in a Large Cohort of HIV-1—Positive Persons in Uganda". doi: 10.1086/340130 . Retrieved 26 May 2022.
  29. ↑ Kaleebu, Pontiano; Ross, Amanda; Morgan, Dilys; Yirrell, David; Oram, Jon; Rutebemberwa, Alleluiah; Lyagoba, Fred; Hamilton, Laura; Biryahwaho, Benon; Whitworth, James (16 February 2001). "Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort". AIDS. 15 (3): 293–299. doi: 10.1097/00002030-200102160-00001 . ISSN   0269-9370. PMID   11273208. S2CID   5761147.
  30. ↑ Weber, J; Fenyö, E M; Beddows, S; Kaleebu, P; Björndal, A (1996). "Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization". Journal of Virology. 70 (11): 7827–7832. doi:10.1128/jvi.70.11.7827-7832.1996. ISSN   0022-538X. PMC   190853 . PMID   8892904.
  31. ↑ Uganda Virus Research Institute. "Kaleebu Receives Medal of Service on Labour Day". Uganda Virus Research Institute. Retrieved 26 May 2022.
Political offices
Preceded by Director Uganda Virus Research Institute
2016 - Present		Succeeded by
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.